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Introduction 
In 1989-90 our group reported that tacrolimus (FK 506) 
could systematically control liver allograft rejection that 
had been intractable despite conventional cyclosporin-
based immunosuppression. 1,' The "rescued" patients were 
maintained on tacrolimus, and manifested no unique or 
unexpected toxicity. Consequently, a pilot trial was begun 
in which tacrolimus was substituted for cyclosporin from 
the time of operation. By early 1990, nearly 200 liver, 
kidney, and other kinds of organ recipients who had been 
entered had superior actuarial survival, lower requirement 
for prednisone, and better quality of life than observed in 
our past experience.'" The upgrading of outlook after liver 
transplantation' was as obvious as when cyclosporin 
succeeded azathioprine as the baseline immuno-
suppressant a decade before.' By November, 1993, 1391 
primary liver-transplant recipients had been treated in 
Pittsburgh with the new drug.' Only 35 (2'5%) of the 
patients crossed over from tacrolimus to cyclosporin and 
15 of these changed back when rejection supervened. 
The keystone management principle 
The new drug was user friendly. As with all previous 
baseline immunosuppressants,7-9 the management secret 
with tacrolimus was administration of doses up to the 
limit imposed by the drug's toxicity. Dose-manoeuvrable 
prednisone or other adjuvant agents were then added as 
needed to control or reverse rejection, or given 
prophylactically. Because the dose-limiting side-effects of 
cyclosporin1O and tacrolimus3•4,1l,12 were the same 
(nephrotoxicity, neurotoxicity, and diabetogenicity), these 
organ-system-specific toxic manifestations could be used 
from the first day of treatment to determine dose ceilings; 
the occurrence of rejection helped to establish the floor. 
The folly of making invidious toxicity comparisons 
between cyclosporin and tacrolimus when the scales could 
be tilted one way or the other by ratcheting the doses up 
or down was self-evident.12 The only adverse effects 
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observed exclusively with one but not the other drug were 
dose-related hirsutism, gingival hyperplasia, and facial 
brutalisation with cyclosporin. 1O 
It was easy, as it had been a decade earlier with 
cyclosporin,13 to deduce the meaning of trough plasma 
and blood concentrations (the plasma/blood ratio was 
about 0·1) and to relate these to toxic manifestations, 
rejection, and the preceding tacrolimus dose. When we 
realised that the first Pittsburgh patients had been 
overdosed, this was corrected in subsequent cases within a 
few postoperative days or hours by responding to the 
clinical events with flexible dosing. Nevertheless, we had 
lowered both the starting intravenous and oral doses in 
Pittsburgh by January, 1990;12 subsequently these were 
reduced again. 14 
These were important revisions no matter what the 
transplanted organ but especially so with the liver because 
the metabolism of tacrolimus is more dependent than that 
of cyclosporin on good hepatic function. 12,15,16 In addition, 
absorption of tacrolimus is little disturbed compared with 
that of cyclosporin by the absence of bile or by intestinal 
disorders. 15 These and other details of the 
pharmacokinetics of tacrolimus, dose ranges, appropriate 
management strategies, and adverse events were well 
worked through by the time of meetings to organise 
multi centre trials in March, 1990. 3 weeks later, the same 
data were presented to the American Surgical Association 
(on April 5, 1990) and a manuscript was published 
5 months later on the eve of the multi centre trials. 
The Pittsburgh trials and beyond 
By the time the multi centre investigations began in late 
August (North America) and September (Europe), 1990, 
our Pittsburgh randomised trial was more than half-
finished. 14 This single-centre trial followed a crisis that 
erupted during the summer and autumn of 1989 in our 
centre and at the US Food and Drug Administration 
(FDA). The problem was caused by the mass referral to 
Pittsburgh from other centres of dozens of patients 
needing tacrolimus rescue therapy. Understandably, the 
drug was being demanded by directors of other 
programmes. The only investigational new drug CIND) 
licence in existence at the time had been issued to TES, 
who could not legally distribute tacrolimus secondarily. 
Moreover, Fujisawa (the manufacturer) had not yet 
decided whether to proceed with the drug's development 
because of reports from Europe of toxicity in animals. At 
our request and with the support of Fujisawa, which 
expedited its own IND, the FDA placed tacrolimus on the 
fast-track for evaluation. However, the extent of testing 
required to establish safety and efficacy became 
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contentious. A controlled-rescue trial that would abandon 
half the patients to control status was not a savoury 
prospect. In addition, pressure had begun to mount to 
force tacrolimus to jump through hoops similar to 
(although more constrictive than) those negotiated by 
cyclosporin nearly 10 years earlier. 
Eventually, an FDA advisory committee recommended 
two multi centre randomised trials that had little bearing 
on the life-saving rescue capability of tacrolimus that 
qualified it for the FDA fast-track. Tacrolimus and 
cyclosporin, given from the time of liver transplantation, 
would be compared head to head. At FDA request, the 
protocol shown in figure 1 was prepared in Pittsburgh for 
this purpose, formally submitted to the FDA in 
November, 1989, and approved 1 month later. The 
document was a product of administrative pressure, and 
was written in a climate of anxiety. The ethical quandary 
of randomising treatment to "life stake" liver transplant 
recipients was similar to that encountered when 
cyclosporin replaced azathioprine as the principal 
immunosuppressant. l7 Realising that we considered the 
superiority of tacrolimus to be settled, the FDA granted 
the Pittsburgh team's request to be excused from 
participation. " 
The randomisation protocol was implemented at the 
Presbyterian University Hospital (Pittsburgh) in 
February, 1990,l4 at the insistence of the institutional 
review board that governed clinical research at this 
facility. However, the two independent institutional review 
boards at the university's paediatric and veteran's 
hospitals permitted tacrolimus to be used by 
patient's/physician's choice. The bitter split within the 
university came from the recognition that a randomised 
trial was not ethical in the absence of equipoise-ie, in the 
absence of substantial uncertainty about the relative 
benefit of the treatments compared. At the insistence of 
the clinicians caring for the patients, a multi-institutional 
"patients' rights committee" (consisting of faculty 
members at University of Pittsburgh, Carnegie Mellon 
University, and Harvard Medical College) was convened 
to evaluate the results every 3 months and make 
recommendations to the institutional review board about 
continuation or stoppage of the trial. 
The safety and efficacy comparison of the competing 
drugs was ensured by equalisation at the outset of all 
treatment variables except the competing drugs (figure 1) 
and by clear definition of end-points. More importantly, 
the patients were protected by allowing them early access 
to whichever drug had the better therapeutic index. By 
the time the trial was prematurely closed in 1991 at the 
recommendation of the oversight committee, 154 patients 
had been randomised. The result, analysed by intention 
to treat, will be reported in detail elsewhere. Massive 
crossover from cyclosporin to tacrolimus left only 24 
patients on cyclosporin after the first year. There was only 
Prednison.e 
20 mg per day 
Tacrollmus 
0·1 rng/kg perday IV 
Oral optional 
vs 
P ... dnf$Ol'I& 
20 mgper day 
Cyct • .,.ln 
4 rng/kg per day IV 
Oral optional 
Figure 1: Balanced experimental design In Pittsburgh 
randomlsed trial 
IV=intravenous. 
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vs 
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(20() +20 mg} . 
n = 1 n = 10 n = 1 
Adjustments by permission Ad-hoc dose adjustments 
Figure 2: Unbalanced experimental design In multicentre 
trials""· 
American details" shown. A LG=antilymphocyte globulin. n=number of 
centres. 
one crossover from tacrolimus to cyclosporin. 
Throughout the entire 3!-5-year period of study, 
tacrolimus enjoyed a statistically significant (log rank) 
greater freedom from rejection alone or in combination 
with freedom from graft loss and adverse events. 
The multicentre randomised trials 
The FDA-approved Pittsburgh protocol (figure 1) was 
presented and recommended by TES at both multicentre 
organisational meetings in early March, 1990. It was 
rejected in favour of the design depicted in figure 2, For 
the American trial, the cyclosporin arm was uploaded 
with twice the induction doses of prednisone in all twelve 
centres, a third drug (azathioprine) in eleven, and a fourth 
agent (polyclonal ALG) in one. The eight European 
centres also had similar unbalanced and diverse protocols. 
On both sides of the Atlantic, the starting and all 
subsequent cyclosporin doses were left to physician's 
discretion, By contrast, the stipulated starting doses of 
tacrolimus were 50% higher than those being used in 
Pittsburgh, Post-transplant adjustments were to be largely 
contingent on blood-monitoring results that would not be 
available until several days later because the samples were 
to be shipped for analysis to reference laboratories in 
distant cities. Formal starting-dose revisions were not 
made until 30% and 18% of the European and American 
tacrolimus cases had been enrolled, The combination of 
excessive dosage and sluggish response time to toxic 
events III the tacrolimus arm had devastating 
consequences. The trials were saved by the skill of the 
investigators who overrode the protocol's dose 
restrictions, 
The results (as in our Pittsburgh randomised trial) were 
analysed by intention to treat, which protects the original 
randomisation by crediting the end-point outcome to the 
assigned treatment, even in the presence of protocol 
violations. The only legitimate reasons to discontinue 
compilation of end-point data (called censoring or 
termination) were patients' death or loss to follow-up. 
The European report 
A 5% better survival of patients was recorded in the 
tacrolimus arm (46 vs 61 deaths) and a 5% higher graft 
survival. l' The survival advantage was not statistically 
significant, but about 10% of the surviving grafts credited 
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Tacrollmus Cyclosporln 
Randomlsed 263 266 
Tolal censored 83 (31-6%) 102 (38·3%) 
Reasons for censoring 
Death 14 (5,3%) 16 (6·0%) 
2nd transplantation for technical problem 17 (6·5%) 21 (7·9%) 
Adverse event 37 (14,1%) 13 (4·9%) 
Lack of efficacy 6 (2·3%) 32 (12·0%) 
Administrative 9 (3-4%) 20 (7·5%) 
* Data from table 3. 
Table: Reasons given In published report of American 
multlcentre study"" for withdrawal (censoring) for secondary 
end-point analysls* 
to cyclosporin had been rescued with tacrolimus. The 
distorting roles of tacrolimus overdosage and a high rate 
of toxicity were clarified by separate analyses of the early 
(high dose) and late (reduced dose) phases of the trial. 
The statistical analysis, based on the intent-to-treat 
approach, showed significantly greater freedom from 
acute rejection, intractable acute rejection, and chronic 
rejection with tacrolimus. 
The American report 
Published report 
The analysis of this trial" was claimed to be by intention 
to treat, implying that all 529 enrolled patients except the 
64 who died contributed data during the full period of 
study for all stipulated end-points: patients' and graft 
survival, rejection, intractable rejection, need for 
retransplantation, steroid need, and muromonab-CD3 
(OKT3) use. However, the only analyses actually done by 
intent-to-treat were patients' and graft survival, which 
were not significantly different in the two arms. Data on 
all other end-points were heavily censored. Censored data 
included those from a large portion of the 465 patients 
who survived throughout the year of the study bearing 
their original grafts or after successful retransplantation 
(table, which is derived from ref 20). 
Thus, rejection that occurred after a patient, for 
example, experienced an adverse event leading to 
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withdrawal of treatment, or who was withdrawn from the 
trial for any reason, was not counted in the published 
analysis. Inexplicably, only 30 of the 64 deaths and 38 of 
the 52 retransplantations were in the censored list (table). 
The rescue role of tacrolimus in reducing the overall 
incidence of retransplantation was obliquely discussed: 
"The low number of second transplantations for 
refractory rejection may have been due, in part, to the 
effectiveness of tacrolimus in treating patients in the 
cycJosporine group who had refractory rejection". In fact, 
grafts rescued by tacrolimus accounted for 20 (9'5%) of 
the 210 surviving grafts credited by intent-to-treat 
analysis to the cyclosporin arm at the end of the year. 
Inappropriate use of the Kaplan-Meier method 
compounded the problem of secondary end-point 
analysis. Instead of using all the data generated by the 
patients who lived through the duration of the study, end-
points subsequent to censoring were obtained by life-table 
(Kaplan-Meier) calculations. An assumption underlying 
this calculation is that censoring is random with respect to 
treatment assignment. 21 Both the number of patients 
censored (102 cyclosporin vs 83 tacrolimus) and most of 
the reasons were differentially distributed in one 
treatment arm or the other (table). Censoring because of 
adverse events was more frequent in the tacrolimus arm, 
while that because of lack of efficacy and "administrative 
reasons" was more frequent in the cyclosporin arm. 
Reanalysis 
The impression was left by the published American 
account that the better efficacy and greater toxicity of 
tacrolimus essentially balanced each other," which 
prompted us to reanalyse the original database, using 
intent-to-treat methodology throughout. A clearer picture 
emerged. As in the European trial, randomisation 
produced groups that were similar at the outset with 
respect to all important prognostic factors. With the 
"freedom from" formulation of the published study, 
several of its conclusions were confirmed. However, the 
numerical results and their statistical significance were 
different from published for all end-points except for the 
o 
1 Rejection 
2 Death, 
retransplantation 
3 Adverse-event 
withdrawal 
........... 
p = 0·033 
0·27 
0·21 
360 o 
1 Rejection 
2 Death, 
retransplantation 
3 Adverse·event 
withdrawal 
4 Withdrawal for 
all other reasons 
~ .. - Tacrolimus 
- Cyclosporin 
'-
-- . 
-----------.0.24 
0·17 
p = 0·007 
360 
Days after transplantation 
Figure 3: Freedom from various undesirable end'points in reanalysis of American trial 
Log-rank test. 
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1-year patients' (88%) and graft (80·5%) survival. 
Consequently, reanalysis required stepwise restoration of 
all the censored categories shown in the table. On 
reanalysis, freedom from rejection as a single end-point 
was accomplished in 39% compared with 32% of the 
patients randomised to tacrolimus and cyclosporin, 
respectively (figure 3, left), which compares with 32% and 
24% in the published report. When data were 
progressively reinserted from the different categories of 
censored patients in layers 2, 3, and 4 of the reanalysis, 
the "freedom from" curves of both arms progressively 
descended (figure 3). However, tacrolimus' superiority 
was maintained throughout. 
In our reanalysis, restoration of freedom from adverse 
events had an almost immeasurable effect on the gap 
between tacrolimus and cyclosporin that was present 
before restoration. This corrected the impression left by 
the published report that tacrolimus' greater efficacy was 
balanced by increased toxicity. Thus the gap between 
tacrolimus and cyclosporin was similar for all the end-
points in figure 3. 
The most clinically relevant results of the reanalysis are 
shown in figure 4. After I-year of follow-up, 98% of the 
patients randomised to tacrolimus were not diagnosed 
with refractory rejection compared with 87% in the 
competing arm. The log-rank p for all secondary end-
points in the reanalysis indicated that experience of 
treatment failure was significantly more favourable with 
tacrolimus, as evaluated over the full year. The composite 
freedom at I year from the three factors that haunt 
transplant recipients (refractory rejection, retransplan-
tation, and death) was 80% for tacrolimus and 70% for 
cyclosporin (figure 4, right). 
Discussion 
Regulatory agencies increasingly insist on controlled 
randomised trials as a prerequisite for marketing new 
drugs. This policy has powerful support in academic 
circles, for reasons that go beyond intellectual merit. 
Fiscal, administrative, and professional opportunities are 
generated within each component of the regulatory! 
1·00 
0·75 
c: 
0 
t 
0 0·50 0-
e 
a.. 
0·25 
0 
a 
0·98 
-_ .... --"' ......... _- .. 
0·87 
1 Refractory rejection 
p = 0·001 
360 a 
.............. 0·80 
...... _- .. -
..... Tacrolimus 
- Cyclospor;n 
1 Refractory rejection 
2 Death, 
retransplantation 
p = 0·008 
360 
Days after transplantation 
Figure 4: Freedom from refractory rejection and refractory 
rejection plus graft loss (from death or retransplantation) in 
reanalysis of American randomised trial 
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pharmaceutical/academic triad that drives such trials. The 
consequent range of possible conflicts of interest has 
made randomised trials a magnet for criticism. 17,2J-25 The 
most damaging potential allegation has been that such 
studies are frequently carried out to obtain answers that 
are already known. We will not further labour the 
evidence that the tacrolimus/cyclosporin multi centre trials 
were a cruel and expensive example of this syndrome. 
How were: the "subjects" recruited for the investigation? 
Whether informed consent is possible in a captive 
population of patients, such as those on an organ-
transplant waiting list, has been asked before. 17,26 Was 
anything worthwhile achieved by the multi-year detour off 
the developmental highway for tacrolimus that already 
had been cleared for the liver and all the other vital organ 
allografts by the spring of I990? At journey's end, a 
talented group of clinician-investigators in twenty 
different centres had surmounted a learning curve for an 
experimental drug by simply reintroducing flexibility into 
a protocol that by the nature of transplantation biology 
can never be applied in the same way to any two 
recipients. 
Did these randomised trials have an effect opposite to 
the objectives of improved and less expensive care of 
patients? Surprisingly, similar multicentre trials were 
mandated for other transplant indications, organ by 
organ. By thI~ time these started, evidence had accrued 
from twenty-four US kidney-transplant centres with 
access to tacrolimus that the actuarial half-life of cadaver 
renal allografts was projected to be 14 years in recipients 
treated with maintenance tacrolimus versus 8 years with 
any previously available immunosuppressant, including 
cyclosporinY If these projections prove valid, the cost 
savings lost to the taxpayer by the 5-year delay in use of 
tacrolimus for renal transplantation will have been 
immense. 
Besides such ethical ramifications, we ask what 
influence the randomised trial mind-set is having on 
genuine clinical research, the atrophy of which has been 
mourned by Ahrens." Tacrolimus was developed in 
Pittsburgh the old-fashioned way--funded by a National 
Institutes of Health grant (DK 29961) and a grant from 
the Veterans Administration. All clinical fees earned by 
faculty members of the University of Pittsburgh 
Transplantation Institute beyond their full-time salaries 
have always been invested in research rather than taken in 
personal income. This was a pure full-time system. Costs 
of hospital stay were defrayed in the usual ways. 
No contractual financial agreement of any kind was 
ever signed, or even discussed, with representatives of 
Fujisawa, whose sole commitment was a gentleman's 
agreement to supply the investigative drug and up-to-date 
scientific information. The reward for the clean-hands 
policy was freedom from the kind of group-think 
decision-making that resulted in the obfuscating design 
used for the multicentre randomised trials. That 
experimental design ultimately was responsible for the 
American multicentre report that required reanalysis to be 
comprehensible. 
This work was aided by project grant DK 29961 from the National 
Institutes of Health, Bethesda, Maryland, USA. 
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